Semaglutide treatment led to a clinically meaningful and significant reduction in loop diuretic dose over the 52-week treatment period, which along with reductions in NT-proBNP and fewer HF events, suggests disease-modifying effects in obesity-related HFpEF. The gene discussed is NPPB; the disease is hydrops fetalis.